Physician profile
Hany Elbeshbeshy
NPI 1376637744
$758,654.00
in general payments reported to CMS, 2019-2025
16 companies · $315K in 2025
The $315K reported for 2025 was more than what 99% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $38K · 2021: $56K · 2022: $84K · 2023: $68K · 2024: $141K · 2025: $315K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $343K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $99K · Travel and Lodging: $39K · Consulting Fee: $25K · Food and Beverage: $13K · Honoraria: $5,795 · Education: $25.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $342,878.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $98,925.00 |
| Travel and Lodging | $39,038.08 |
| Consulting Fee | $24,742.50 |
| Food and Beverage | $12,570.27 |
| Honoraria | $5,794.59 |
| Education | $25.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159,272.23 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $147,289.34 | 2020-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $127,416.26 | 2022-2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $107,836.77 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $101,294.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Eisai INC. | $79,937.38 | 2019-2025 | |
| Gilead Sciences, INC. | $31,672.54 | 2019-2025 | Livdelzi |
| Exelixis INC. | $3,422.40 | 2019 | |
| Genentech, INC. | $135.52 | 2024 | Itovebi, Avastin, Columvi |
| Novo Nordisk INC | $107.60 | 2022-2024 | Ozempic, Rybelsus |
| Erbe USA INC | $99.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.32 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.85 | 2023 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2023 | |
| Conmed Corporation | $21.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hany Elbeshbeshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.